InSphero’s leadership team combines many years’ scientific and commercial experience in 3D microtissue engineering, cell based assays, laboratory automation, and industry-scale production and quality assurance. It is complemented by the strategic management expertise of our Board of Directors and Strategic Advisory Board members.
Engineer and expert in laboratory automation with 20 years of experience in high-tech startups from chemical processing to medical devices. Jan earned his PhD in Microtechnology and Microfuidics at the University of Neuchêtel.
One of the co-founders of InSphero, Wofgang is expert in production and assay methods for microtissues using laboratory-scale approaches, valuable background in clinical applications of microtissues including islet biology and diabetes drug discovery. Wolfgang earned a PhD in Biochemistry from the University of Zurich.
Qualified Accountant with over 25 years of experience at rapidly growing companies in the technology field. An expert in corporate finance including funding, corporate transactions and M&A, and experienced in systems integration and process reengineering, Oliver earned his MBA at the University of Chicago.
Extensive experience in life sciences, engineering, business innovation & development, operations and new ventures consulting. Held leadership positions in industry (Sanofi) and academia (Massachusetts Institute of Technology, Princeton University) with focus on cell therapy, 3D cellular models/organoids, synthetic biology, human stem cells, biologics and small molecules development, and precision genomic engineering. Patrick earned his PhD in Molecular Infection Biology from the University of Basel.
Life-science professional with more than 15 years industry experience, where he held various positions in sales & marketing, product management and business development. His experience ranges from bioinformatics, in vitro diagnostics, and cell-culture in mid-sized and as well as large corporations. Frank holds a PhD in Molecular Microbiology from ETH Zurich.
A seasoned Quality Assurance and Regulatory Affairs professional with 20+ years of experience in pre-market and post-market product development of life science & biotech products and medical devices, including medical device vigilance and post-market surveillance. Hands-on experience in establishing Quality Systems supporting pre-clinical and clinical product development and product release to market. Marion earned her PhD in Molecular Biology at the University of Zurich and an MBA from Webster University, Geneva.
HR professional with more than 9 years of experience in talent management, learning & development, operational HR, assessment, management development, coaching and training. Katrin earned her PhD in Applied Psychology from the University of Zurich.
Trained biochemist and molecular biologist with extensive experience in product development, characterization and application of 3D microtissues. Simon holds a PhD in molecular biology from the University of Zurich and an MAS in Product Management from ZHAW Zurich.
Experienced scientist and member of the InSphero team since 2012. David has extensive industry expertise in advanced in vitro model development, standardization, and automation. He holds a PhD in molecular biotechnology from ETH Zurich.
Dr. Jens M. Kelm, InSphero AG Co-founder
Dr. Jan Lichtenberg, Chief Executive Officer InSphero AG, Member of the InSphero Management Team
Thomas Pfisterer, Wild Group Management AG
Dr. Jürg Gysi, President of the Board, Switzerland
Former CEO, Promega AG Switzerland. Molecular Biologist with more than 30 years of experience in sales, marketing and management in the biotech industry in Switzerland, Germany and the US.
Beat Schillig, Founder and President IFJ Institute for Young Entrepreneurs
Serial Entrepreneur and Business Angel.
Dr. Thomas Rinderknecht, Senior Partner at Badertscher Rechtsanwälte
Has served on the board of directors of several biotech, pharma and medtech companies, including amongst others Basilea, Speedel AG, Basel, Glycart Biotechnology AG and Ganymed Pharmaceuticals AG. Ph.D. in law from the University of Zurich, admitted to the Bar in Zurich.
Anna Evodokimova, VC Investment Director at Millhouse LLC
Professor Gordon McVie
An international authority on the treatment and research of cancer. Along with Umberto Veronesi, he is the founding editor of ecancermedicalscience, an open access cancer journal from the European Institute of Oncology in Milan.
Dr. Igor Koman
Director of Ariel University’s Institute for Personalized Medicine. Dr. Komen graduated from the Russian Medical University and holds a PhD and DSc in clinical pharmacology.
Charles Qualls, DVM, PhD, DACVP
A toxicology expert who retired as Executive Director of Investigative Toxicology and Pathology at Amgen Inc. Before working at Amgen, Dr. Qualls served as Director of Molecular and Ultrastructural Pathology at GlaxoSmithKline. Dr. Qualls had a distinguished career over two decades in academia prior to moving into the pharmaceutical industry.
Dr. Jean Krutman
Scientific director of the Leibniz Research Institute for Environmental Medicine, Düsseldorf Germany.
Dr. Med. Sci. Frédéric Lévy
Head of Research & Evaluation at Debiopharm International SA and Associate Professor at the Faculty of Biology and Medicine, University of Lausanne with more than 50 peer-reviewed scientific publications. Dr Med Sc, Biochemistry/Immunology and Postdoc at California Institute of Technology.